Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6th, 2020
July 30 2020 - 04:05PM
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the
Company will release results for its second quarter of 2020 ended
June 30, 2020, after the market closes on Thursday, August 6th,
2020, and will hold a conference call to discuss its financial
results at 2:00 p.m. Pacific Time.
To access the conference call, dial toll free (800)
708-4540, five minutes before the conference. The passcode for the
conference call is 49844225.
The call can also be accessed on the Investors page
on the Company’s website www.amphastar.com.
Amphastar is a specialty pharmaceutical company that primarily
develops, manufactures, markets, and sells generic and proprietary
injectable and inhalation products, including products with high
technical barriers to market entry. Most of the Company’s products
are used in hospital or urgent care clinical settings and are
primarily contracted and distributed through group purchasing
organizations and drug wholesalers.
Forward Looking Statements
All statements in this press release and in the conference call
referenced above that are not historical are forward-looking
statements, including, among other things, statements relating to
the Company’s expectations regarding future financial performance,
backlog, sales and marketing of its products, market size and
growth, the timing of FDA filings or approvals, including the DMFs
of ANP, the timing of product launches, acquisitions and other
matters related to its pipeline of product candidates, its share
buyback program and other future events, such as the impact of the
COVID-19 pandemic and related responses of business and governments
to the pandemic on our operations and personnel, and on commercial
activity and demand across our business operations and results of
operations. These statements are not historical facts but rather
are based on Amphastar’s historical performance and its current
expectations, estimates, and projections regarding Amphastar’s
business, operations and other similar or related factors. Words
such as “may,” “might,” “will,” “could,” “would,” “should,”
“anticipate,” “predict,” “potential,” “continue,” “expect,”
“intend,” “plan,” “project,” “believe,” “estimate,” and other
similar or related expressions are used to identify these
forward-looking statements, although not all forward-looking
statements contain these words. You should not place undue reliance
on forward-looking statements because they involve known and
unknown risks, uncertainties, and assumptions that are difficult or
impossible to predict and, in some cases, beyond Amphastar’s
control. Actual results may differ materially from those in
the forward-looking statements as a result of a number of factors,
including those described in Amphastar’s filings with the
Securities and Exchange Commission, including in the Annual Report
on Form 10-K for the year ended December 31, 2019 filed with the
SEC on March 16, 2020. In particular, the extent of COVID-19’s
impact on our business will depend on several factors, including
the severity, duration and extent of the pandemic, as well as
actions taken by governments, businesses, and consumers in response
to the pandemic, all of which continue to evolve and remain
uncertain at this time. You can locate these reports through the
Company’s website at http://ir.amphastar.com and on the SEC’s
website at www.sec.gov. The forward-looking statements in
this release speak only as of the date of the release. Amphastar
undertakes no obligation to revise or update information in this
press release or the conference call referenced above to reflect
events or circumstances in the future, even if new information
becomes available or if subsequent events cause Amphastar’s
expectations to change.Contact:
William J. PetersChief Financial Officer(909) 980-9484
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From Mar 2023 to Mar 2024